Select a Topic

Featured Discussions

Arthritis & Rheumatology

• Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. M Hoff et al. BMC Musculoskelet Disord 2011 1;12():54
  Panelists: Graciela Alarcon, M.D., M.P.H; Joel Kremer, MD
• Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. R Westhovens et al. J Rheumatol 2009 4;36(4):736-42
  Panelists: Joel Kremer, MD; Arthur Weaver, M.D., M.S., F.A.C.P., M.A.C.R.

MORE...

Cancer

• Adjuvant chemotherapy in older women with early-stage breast cancer. HB Muss et al. N Engl J Med 2009 5;360(20):2055-65
  Panelists: Hyman Muss, MD; Lawrence Shulman, MD

Cardiovascular Disease

• The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. C Baigent et al. Lancet 2011 6;():
  Panelists: Colin Baigent, FFPH, FRCP; Peter McCullough, M.D., M.P.H.
• Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. G Montalescot et al. Thromb Haemost 2010 1;103(1):213-23
  Panelists: Robert Chilton, D.O.; Gilles Montalescot, MD, PhD

MORE...

Dermatology

• Innovative uses of imiquimod. RB Vender et al. J Drugs Dermatol 2005 1;4(1):58-63
  Panelists: Roy Grekin, MD; Philip LeBoit, MD; Ronald Vender, MD, FRCPC

Diabetes

• Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. MA Nauck et al. Diabetes Care 2011 9;34(9):2015-22
  Panelists: Michael Nauck, Prof. Dr. med.; Kathleen Wyne, M.D., Ph.D.
• Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. E Ferrannini et al. Diabetes Care 2010 10;33(10):2217-24
  Panelists: Michael Bloch, MD; John P. H. Wilding, DM FRCP

MORE...

Growth-Related Disorders

• Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. P Cohen et al. J Clin Endocrinol Metab 2007 7;92(7):2480-6
  Panelists: David Allen, M.D.; Steven Chernausek, MD; Pinchas Cohen, M.D.
• Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. D Simon et al. J Clin Endocrinol Metab 2007 7;92(7):2567-73
  Panelists: David Allen, M.D.; Paul Czernichow, MD; Stephen LaFranchi, M.D.

MORE...

Nephrology

• Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). M Goicoechea et al. Kidney Int Suppl 2005 1;(93):S35-8
  Panelists: George Bakris, MD; Peter McCullough, M.D., M.P.H.; Donal Reddan, MD
• Rosuvastatin-induced arrest in progression of renal disease. DG Vidt et al. Cardiology 2004 1;102(1):52-60
  Panelists: George Bakris, MD; Peter McCullough, M.D., M.P.H.; Donal Reddan, MD

MORE...

Obesity

• Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. SM Grundy et al. Circulation 2004;109:551-556.
  Panelists: Roger Blumenthal, M.D.; Scott Grundy, M.D., Ph.D.; Peter Toth, M.D., Ph.D.
• The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. JE Manson et al. Arch Intern Med 2004 2;164(3):249-58
  Panelists: Graciela Alarcon, M.D., M.P.H; Vera Bittner, M.D., M.S.P.H.; JoAnn Manson, M.D., Dr.P.H., M.P.H.

Primary Care

• Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. B Dahlöf et al. Lancet 2005 9;366(9489):895-906
  Panelists: Robert Chilton, D.O.; Jerome Cohen, M.D.; Peter Sever, PhD, FRCP
• Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. JM Kremer et al. Arthritis Rheum 2005 8;52(8):2263-71
  Panelists: Graciela Alarcon, M.D., M.P.H; John Cush, M.D.; Joel Kremer, MD

MORE...

Listen To What
Experts Have To Say

BioDiscussion brings together experts and authors to discuss topics and papers of most current interest that have the highest scientific impact on their respective fields. Each discussion explores a topic in a non-scripted manner, allowing experts the opportunity to express their opinions and share their knowledge with listeners.

Each discussion is available on-demand and has several features which enhance the educational content. Downloadable PowerPoint¨ slides, transcript, and links to other topic resources allow for a truly in-depth learning experience. FREE CME is also a part of each discussion.

If you have not already been sent an access code to enter the site, please click here to request privileges to this site.

Featured Review

BioCritique helps you stay on top of significant advances in biomedical research. Leading scientists and clinicians in major therapeutic areas select and review the latest 'impact' articles on an ongoing basis.